MedTrace Logo

Mass Balance Study With MT-7117

NCT03503266 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-05-15

No results posted yet for this study

Summary

This is a single-centre, open-label, mass balance study in healthy male subjects utilising a single oral dose of \[14C\] MT 7117.

Conditions

  • Healthy Volunteer

Interventions

DRUG

[14C] MT-7117

14-C MT-7117

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma America Inc.

    lead INDUSTRY

Principal Investigators

  • General Manager · Mitsubishi Tanabe Pharma Europe Ltd

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-23
Primary Completion
2018-05-11
Completion
2018-05-11

Countries

  • United Kingdom

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03503266 on ClinicalTrials.gov